Exbio — Research products — Antibodies — Other intracellular antigens — Anti-PAG1 Purified

Anti-PAG1 Purified

Anti-PAG1 Purified
Regulatory status
RUO
Antigen
PAG1
Clone
MEM-255
Format
Purified
Reactivity
Human
Application
FC, WB, IHC(P)
Variant
0.1 mg
11-347-C100
In stock
180.00 USD
0.025 mg
11-347-C025
Out of stock
90.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD
0.1 mg
11-261-C100
In stock
90.00 USD
Contact distributor
Product details
Images
References
Isotype
Mouse IgG2a
Specificity
The antibody MEM-255 recognizes an epitope (aa 235-280) of Csk-binding protein (Cbp) located in the cytoplasmic domain, also known as protein associated with glycosphingolipid-enriched microdomains (PAG).
Application
FC, WB, IHC(P)
Application details
Flow cytometry: Recommended dilution: 2 μg/ml; intracellular staining, permeabilization required.
Immunohistochemistry (paraffin sections): Positive tissue: tonsil, spleen.
Western blotting: Csk binding protein is an ubiquitously expressed 46 kDa transmembrane adaptor protein present in membrane microdomains (rafts), which, however, migrates on SDS-PAGE gels anomalously as an 80 kDa molecule.
Reactivity
Human
Negative species
Mouse, Rat, Cow
Immunogen
Recombinant intracellular fragment (aa 97-432) of human Cbp (PAG).
Other names
CBP, PAG
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
11-347_IHC
Immunohistochemistry staining (paraffin-embedded sections) using anti-Cbp/PAG (MEM-255). Cbp/PAG is expressed in germinal centers of lymph node lymphoid follicle and in follicular lymphoma (it is absent from mantle zone). Cbp/PAG is also expressed more weakly in T cells in tonsil and the thymic medulla.

General references:

Simeoni L, Smida M, Posevitz V, Schraven B, Lindquist JA: Right time, right place: the organization of membrane proximal signaling. Semin Immunol. 2005 Feb;17(1):35-49.
PubMed
Horejsí V, Zhang W, Schraven B: Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat Rev Immunol. 2004 Aug;4(8):603-16.
PubMed
Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A: Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol. 2003 Mar;23(6):2017-28.
PubMed
Baumgartner M, Angelisova P, Setterblad N, Mooney N, Werling D, Horejsi V, Langsley G: Constitutive exclusion of Csk from Hck-positive membrane microdomains permits Src kinase-dependent proliferation of Theileria-transformed B lymphocytes. Blood. 2003 Mar 1;101(5):1874-81.
PubMed

Product specific references:

Semac I, Palomba C, Kulangara K, Klages N, van Echten-Deckert G, Borisch B, Hoessli DC: Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003 Jan 15;63(2):534-40.
PubMed
Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, Scherer J, Shevchenko A, Hilgert I, Cerny J, Drbal K, Kuramitsu Y, Kornacker B, Horejsi V, Schraven B: Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med. 2000 May 1;191(9):1591-604.
PubMed
Brdickova N, Brdicka T, Andera L, Spicka J, Angelisova P, Milgram SL, Horejsi V: Interaction between two adapter proteins, PAG and EBP50: a possible link between membrane rafts and actin cytoskeleton. FEBS Lett. 2001 Oct 26;507(2):133-6.
PubMed
Schatzlmaier P, Supper V, Göschl L, Zwirzitz A, Eckerstorfer P, Ellmeier W, Huppa JB, Stockinger H: Rapid multiplex analysis of lipid raft components with single-cell resolution. Sci Signal. 2015 Sep 22;8(395):rs11
PubMed
Svec A, Velenská Z, Horejsí V: Expression pattern of adaptor protein PAG: correlation between secondary lymphatic follicle and histogenetically related malignant lymphomas. Immunol Lett. 2005 Aug 15;100(1):94-7.
PubMed
Tedoldi S, Paterson JC, Hansmann ML, Natkunam Y, Rudiger T, Angelisova P, Du MQ, Roberton H, Roncador G, Sanchez L, Pozzobon M, Masir N, Barry R, Pileri S, Mason DY, Marafioti T, Horejsi V: Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood. 2006 Jan 1;107(1):213-21. Epub 2005 Sep 13.
PubMed
Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A: Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol. 2003 Mar;23(6):2017-28.
PubMed
Variant
0.1 mg
11-347-C100
In stock
180.00 USD
0.025 mg
11-347-C025
Out of stock
90.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD
0.1 mg
11-261-C100
In stock
90.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product